GammaDelta Therapeutics Archives

cancer immunotherapy gammadelta therapeutics adaptate biotherapeutics

News and Trends 16 Oct 2019

GammaDelta Therapeutics Spins Out Cancer Immunotherapy Biotech

The UK biotech GammaDelta Therapeutics has founded Adaptate Biotherapeutics to develop cancer immunotherapies based on antibodies that boost a rare type of immune cell. Adaptate Biotherapeutics is a spin-out of GammaDelta Therapeutics, a London company founded in 2016 that specializes in using a rare type of immune cells, known as gamma delta T-cells, to fight […]

October 16, 2019 - 2 minutesmins - By Jonathan Smith

In Depth 11 Jun 2019

Gamma Delta T Cells: A New Hope Against Cancer

A new wave of therapies based on a unique type of immune cells, called gamma delta T cells, has the potential to treat cancer with stronger responses and fewer side effects. Immunotherapies based on T cells are becoming a huge trend in the treatment of cancer, especially CAR-T cells. These genetically-modified T cells have shown […]

June 11, 2019 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 Jul 2018

Abingworth Closes €268M to Invest in Life Science Companies

Abingworth has closed $315M (€268M) for its most recent fund, Abingworth Bioventures VII, which invests in European and US life science companies. In the current fundraising, Abingworth surpassed its target of $300M. The new fund will invest in life science companies in all stages of development, including early and late-stage venture deals. The company plans to […]

July 9, 2018 - 2 minutesmins - By Alexander Burik

Best in Biotech 9 Jan 2018

Happy 2018, Here Are the Top 9 European Biotech Companies To Watch

As the 2017 reports roll in, we’re already turning our gaze to 2018. These are the top European biotech companies to watch in the new year. The results from last year are rolling in, and it seems to be a mixed bag. Generalist investors are backing away from biotech, but the FDA approved a record […]

January 9, 2018 - 5 minutesmins - By Evelyn Warner

Francis Crick institute Veronique Birault Head of Translation

Interview 24 Jul 2017

Discussing Open Science with the Head of Translation at The Francis Crick Institute

Officially opened less than a year ago, The Francis Crick Institute is already conducting top-level biomedical research, has launched two spin-outs and struck research partnerships with both AstraZeneca and GlaxoSmithKline. I spoke to the Head of Translation, Dr. Véronique Birault, to learn more about the Crick’s unique model of translation and the key for its […]

July 24, 2017 - 5 minutesmins - By Clara Rodríguez Fernández

Interview 12 Jun 2017

This Italian Academic-turned-CEO also Launched 7 Cancer Drugs at GSK

Paolo Paoletti might have been forced to reconsider his career as a professor in medicine, but academia’s loss was biopharma’s gain! Before becoming CEO of one of London’s most exciting biotechs, GammaDelta Therapeutics, Paolo Paoletti had a long run through the corporate ranks of pharma. He was coaxed out of academic medicine to join Eli […]

June 12, 2017 - 9 minutesmins - By Evelyn Warner

GammaDelta Therapeutics Takeda Collaboration 1

More News! 9 May 2017

British Biotech Startup Partners with Takeda to Advance its T Cell Platform

GammaDelta Therapeutics and Takeda have formed a strategic collaboration to develop a novel T cell platform, which is based on gamma delta (γδ) T cells. Based in London, GammaDelta Therapeutics builds on the work of Adrian Hayday and Oliver Nussbaumer of Kings College London and The Francis Crick Institute. Backed by the huge British VC […]

May 9, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 19 Sep 2016

Abingworth launches UK Immuno-Oncology Startup with Seed Funding

Just when we thought it couldn’t become any more intense, the field of immuno-oncology is heating up. VC giant Abingworth has seeded a new UK startup, GammaDelta Therapeutics, to bring its T cell therapy to the clinic. Abingworth, a huge British VC firm, has thrown its weight behind a new London-based immuno-oncology startup, GammaDelta Therapeutics. […]

September 19, 2016 - 3 minutesmins - By Evelyn Warner

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us